Nucala Now Available for Severe Asthma

GlaxoSmithKline announced the launch of Nucala (mepolizumab) for the treatment of patients aged ≥12 years with severe asthma with an eosinophilic phenotype.

GlaxoSmithKline announced the launch of Nucala (mepolizumab) subcutaneous injection for the treatment of patients aged ≥12 years with severe asthma with an eosinophilic phenotype. 

Nucala, the first biologic add-on therapy approved for this condition, is administered by a healthcare professional every 28 days. It is not indicated to treat other eosinophilic conditions or to relieve acute bronchospasm or status asthmaticus. 

RELATED: Nucala Approved for Severe Asthma

Nucala is a humanized interleukin-5 antagonist monoclonal antibody that is produced by recombinant DNA technology in Chinese hamster ovary cells. It reduces severe asthma attacks by decreasing the production and survival of eosinophils. 

Nucala is available as 100mg preservative-free, lyophilized powder for reconstitution in single-dose vials. 

For more information call (888) 825-5249 or visit